@AASLDtweets great in person #TLM22 meeting. We are getting more serious about #HCV elimination, there are more options for #HCC and #BTC than ever before and we still don’t have treatments for #NAFLD. We’re not even sure we like the name…See you in Boston next year!
@AASLDtweets Collins plan calls for acceleration of #HCV diagnostics including point of care RNA and core Ag as well as a “national prescription model”. 5 year funding for national plan underway #TLM22
@AASLDtweets @JagChhatwal presents mathematical simulation model for acceleration of #HCV treatment which could result in averting 91,000 deaths and 108,000 #HCC cases by 2050.WOULD ALSO SAVE 13.2 BILLION DOLLARS! #TLM22
@AASLDtweets Dr. Francis Collins: “I think I could, as an internist, treat #HCV and monitor the patient effectively”. We agree! Need to make #HCV therapy widely accessible through elimination of barriers and education #TLM22
@AASLDtweets after an introduction by @AASLDPresident, Dr. Francis Collins is at the #TLM22 podium outlining his vision for #HCV elimination in the US
@AASLDtweets @KnowledgeNash spreading awareness and advocacy about the defining liver disease of our time #NAFLD #NASH #FattyLiver #TLM22
@AASLDtweets November is #alpha1awareness month. Thank you @AlphaFriend and all those raising awareness and advocating for better diagnosis and therapy! #TLM22
@AASLDtweets genome wide cfDNA fragmentome #MachineLearning is interesting in that it appears to detect @BCLC_group #HCC early stages 0/A with high sensitivity and specificity. If these data hold true, may replace or augment our current screening/surveillance strategies #TLM22
@AASLDtweets could a genome wide machine learning approach augment our yield compared to #HCC screening and surveillance via epigenetic platforms? Cell free DNA #fragmentome technology is attempting to answer this question #TLM22
@AASLDtweets it’s a great day to sport your @AASLDFoundation swag for what promises to be another outstanding #TLM22 program.
@AASLDtweets great conversation at the #TLM22 #HCV patient poster tour! @TatyanaKushner @scottasuckow @OHIOLIVER @SDLiver
@AASLDtweets I wasn’t expecting a giant digital bust of @GIcancerDoc greeting me when I walked into #TLM22 today but I’m glad it did!
@AASLDtweets @UnitedPorphAssc advocating and educating about the porphyrias . We can all do better to diagnosis this now treatable and debilitating disease #TLM22
@AASLDtweets another exciting day of #TLM22 starting with the presidential plenary as a highlight @DrHuangDQ @docbinujohn @norahterrault @CarlaBradyMD
@AASLDtweets it is my firm belief that a strong shower water pressure sets a positive tone for the day. Are you listening @Marriott? #FirstWorldProblems #TLM22
@AASLDtweets @KowdleyMd highlights the pitfalls and advantages of ELF (I’m a fan). Major plus is that it has good correlation with long term prognosis. Cutoff 9.8 misclassifies 10% as having advanced fibrosis. Performs >FIB-4 >Pro-C3 #TLM22
@AASLDtweets @saulkarpen Mainly ABCB4 (PFIC-3) type but also other mutations found in up to 28% adults with unexplained cholestasis or other liver injury pattern. Not something I have ever tested for in this setting but maybe I should #TLM22
All ⭐️ cast for @AASLDtweets PGC in am @DrLoomba @DrCynthiaLevy @RotonyaC @laurakulik1 @KowdleyMd @saulkarpen @DinaTiniakos @marurinella @norahterrault @LewisRobertsMD @SeragHashem @JuanAbraldes @MassimoPinzani @AutoImmuneLiver @phil_newsome7 @GIChiefNid @elizabeth_verna #TLM22
#TLM22 will be my 23rd @AASLDtweets meeting (21 in person) but I’ve never had to fly 48 hours before the official start (due to a ridiculously busy pre-conference schedule). Shockingly, my @United flight is on time! Safe travels to all! #LiverTwitter
@AASLDtweets dropping in am, all things liver and #SoMe with the usual suspects @HowardTLeeMD @christopherkoh @sjhatch_joanne @AtoosaRabiee @MariaYatacoMD @hepatitisihelpc @AustinChiangMD
11/2/22, 8:00 AM Social Media and Technology in Hepatology #LiverMtg22 or #TLM22 or #TLMdX
A whole lot happening in the #biliarytractcancer space. A must attend for all interested in hepato-oncology @MiteshBorad
11/4/22, 10:45 AM — Novel Targeted and Combination Therapies for #Cholangiocarcinoma #TLM22
@AASLDtweets how does the new @BCLC_group algorithm move the needle in liver transplantation? @ma5RN
11/4/22, 10:00 AM — #HCC : Implications of BCLC 2022
on Liver Transplantation #TLM22
@AASLDtweets great session on all thing #NAFLD NITs @DrLoomba @NoureddinMD @AlinaAllenMD @AlkhouriNaim @Camilla_Dalby
11/7/22, 11:30 AM — Parallel 24: Diagnostics and Biomarkers of NAFLD #TLM22
